Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Bellevue Group AG

Bellevue Group AG trimmed its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 23.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 485,050 shares of the company's stock after selling 144,708 shares during the quarter. Bellevue Group AG owned 0.85% of Structure Therapeutics worth $13,155,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Boxer Capital Management LLC bought a new position in Structure Therapeutics during the 4th quarter worth about $13,560,000. Marshall Wace LLP increased its holdings in Structure Therapeutics by 339.6% during the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after buying an additional 450,531 shares during the period. Foresite Capital Management VI LLC bought a new position in Structure Therapeutics in the fourth quarter worth approximately $11,390,000. Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 230.0% in the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after acquiring an additional 380,115 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Structure Therapeutics by 29.4% during the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after purchasing an additional 322,601 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded down $2.23 during trading on Tuesday, reaching $25.32. The stock had a trading volume of 1,125,611 shares, compared to its average volume of 923,976. The business has a fifty day moving average price of $20.73 and a 200-day moving average price of $27.20. The stock has a market cap of $1.45 billion, a PE ratio of -34.22 and a beta of -1.69. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GPCR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday. They set a "buy" rating and a $60.00 price objective for the company. William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $78.63.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.